Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2017-11-13 Interim / Quarterly Rep…
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2017
2017-11-13 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions an "Other Events" section describing a press release about FDA responses related to an Investigational New Drug application. The document is short (3480 characters) and primarily serves to announce the press release rather than provide detailed financial data or a full report. There are no financial statements or comprehensive financial analysis included. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-11-01 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text indicates the filing is about a press release announcing the submission of a Clinical Trial Authorization request in Poland. The document is short (3191 characters) and primarily serves as an announcement of an event rather than a detailed financial report or earnings release. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-10-24 English
Regulatory Filings 2017
Regulatory Filings
2017-10-24 English
POS AM
Transaction in Own Shares Classification · 100% confidence The document is a Post-Effective Amendment No. 1 to Form S-1 Registration Statement filed with the SEC. It updates a previously effective registration statement related to the offering of securities, specifically common stock and warrants. The document includes detailed information about the securities offered, use of proceeds, risk factors, and other disclosures typical of a registration statement amendment. It is not a financial report, earnings release, or management discussion, but rather a regulatory filing related to capital raising and securities registration. Therefore, the appropriate classification is 'POS' for Transaction in Own Shares, as it relates to the registration and offering of securities including warrants and common stock issuable upon exercise of those warrants.
2017-10-17 English
OWNERSHIP DOCUMENT
Director's Dealing
2017-10-06 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.